Physician profile
Jon A Rumohr
NPI 1891842761
$1,633.09
in general payments reported to CMS, 2019-2025
26 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $39.55 · 2021: $103 · 2022: $171 · 2023: $531 · 2024: $363 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $198.90 | 2019-2025 | General - Vascular Intervention, Spaceoar Vue System - 10ml |
| Dornier Medtech America, INC | $180.23 | 2022-2023 | Dornier Medtech |
| Abbvie INC. | $175.18 | 2019-2025 | Lupron Depot |
| Axonics, INC. | $168.89 | 2022-2023 | Axonics |
| Medtronic, INC. | $137.01 | 2023-2024 | Interstim |
| Calyxo, INC. | $101.01 | 2024-2025 | Cvac Aspiration System |
| Teleflex LLC | $70.88 | 2023-2024 | Urolift |
| Laborie Medical Technologies Corp. | $64.50 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Tolmar, INC. | $49.25 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $45.49 | 2023 | Xiaflex, Aveed, Edex |
| Progenics Pharmaceuticals, INC. | $44.56 | 2023-2024 | Pylarify |
| Myriad Genetic Laboratories, INC. | $43.83 | 2021-2023 | Prolaris |
| Urogen Pharma, INC. | $41.00 | 2023-2024 | Jelmyto |
| Astellas Pharma US INC | $35.58 | 2022-2023 | Myrbetriq |
| Coloplast Corp | $33.13 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $30.93 | 2021 | |
| Ambu INC. | $29.53 | 2024 | |
| Janssen Biotech, INC. | $27.13 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $26.82 | 2024 | Gemtesa |
| Ferring Pharmaceuticals INC. | $22.78 | 2024 | Adstiladrin |
| 180 Medical, INC. | $19.86 | 2019 | |
| Olympus America INC. | $19.85 | 2021 | |
| Koelis INC. | $18.55 | 2025 | |
| Janssen Scientific Affairs, LLC | $18.10 | 2019 | |
| Blue Earth Diagnostics | $15.06 | 2020 | |
| Immunitybio, INC. | $15.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Rumohr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.